Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects.

Abstract:

INTRODUCTION:Benign prostate hyperplasia (BPH) is one of the most prevalent diseases in aging men. It may adversely affect quality-of-life due to the presence of low urinary tract symptoms (LUTS) and its effects on sexuality. AREAS COVERED:The impact of α1-blockers, 5α-reductase inhibitors (5-ARI), and phosphodiesterase 5 inhibitors (PDE-5i) on erectile and ejaculatory functions in men with BPH are covered. Endocrinological aspects have also been addressed, including the management of hypogonadism, which affects many patients with BPH, and the impact of the use of 5-ARI use on bone health. EXPERT OPINION:The adverse-event profile of α1-blockers depends on their affinity for the α1-adrenoceptors rather than selectivity. The probability of ejaculatory dysfunction is highest with silodosin than other nonselective drugs (tamsulosin, alfuzosin, doxazosin, and terazosin). Concerning the impact of finasteride and dutasteride on sexual desire, erectile function, and ejaculation, the vast majority of the studies have shown a low prevalence of treatment-related adverse events. Due to the benefits of erection, PDE5i represents the perfect class of drugs for the treatment of LUTS-BPH in patients with erectile dysfunction. Testosterone replacement therapy could be considered in some hypogonadal patients with BPH. Finally, current evidence support the safety of 5-ARI on bone tissue.

authors

La Vignera S,Aversa A,Cannarella R,Condorelli RA,Duca Y,Russo GI,Calogero AE

doi

10.1080/14656566.2020.1817382

subject

Has Abstract

pub_date

2020-09-09 00:00:00

pages

1-11

eissn

1465-6566

issn

1744-7666

pub_type

杂志文章
  • The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice.

    abstract:INTRODUCTION:Acute diarrhea remains a major problem in children and is associated with substantial morbidity, mortality and costs. While vaccination against rotavirus could reduce the burden of the disease, the persistent impact of intestinal infections requires effective treatment in adjunct to oral rehydration soluti...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.634800

    authors: Guarino A,Dupont C,Gorelov AV,Gottrand F,Lee JK,Lin Z,Lo Vecchio A,Nguyen TD,Salazar-Lindo E

    更新日期:2012-01-01 00:00:00

  • Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.

    abstract::Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.1.95

    authors: Barst RJ

    更新日期:2007-01-01 00:00:00

  • Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

    abstract:OBJECTIVE:Mycophenolic acid (MPA), the active form of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), is used to treat systemic lupus erythematosus (SLE). MMF and EC-MPS pharmacokinetics were examined to devise guidance for therapeutic drug monitoring (TDM) for SLE patients with normal ren...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656561003592144

    authors: Djabarouti S,Duffau P,Lazaro E,Chapouly C,Greib C,Viallard JF,Pellegrin JL,Saux MC,Breilh D

    更新日期:2010-04-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Role of aprotinin in the management of patients during and after cardiac surgery.

    abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.7.1353

    authors: Punjabi PP,Wyse RK,Taylor KM

    更新日期:2000-12-01 00:00:00

  • Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.

    abstract::The purine nucleoside analogues, either alone or in combination with other chemotherapeutic agents, are increasingly used in the treatment of patients with indolent B-cell lymphoproliferative disorders. The initial studies in Waldenström's macroglobulinaemia (WM) are very promising. Approximately 40% of patients who h...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.6.945

    authors: Owen RG

    更新日期:2001-06-01 00:00:00

  • Pharmacotherapy options in pulmonary alveolar proteinosis.

    abstract:INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1757650

    authors: Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

    更新日期:2020-08-01 00:00:00

  • Pharmacological management of Cronkhite-Canada syndrome.

    abstract::Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.3.385

    authors: Ward EM,Wolfsen HC

    更新日期:2003-03-01 00:00:00

  • Pharmacological management of paracoccidioidomycosis.

    abstract::A systemic and endemic emerging mycosis in Latin America, paracoccidioidomycosis, is characterised by its chronicity and by the severity of the disseminated form in healthy individuals, as well as in immunocompromised individuals co-infected with HIV, resulting, in the latter, in a mortality rate in the range of 30 - ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.3.385

    authors: Yasuda MA

    更新日期:2005-03-01 00:00:00

  • Immunosuppressive therapy of childhood idiopathic nephrotic syndrome.

    abstract::Childhood nephrotic syndrome (NS) is a distressing chronic renal disorder with potentially life threatening complications. Over 80% of cases in children are due to minimal change disease and the majority will respond to corticosteroid therapy. Steroid-sensitive NS is considered a relatively benign condition, since pro...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.5.513

    authors: Abeyagunawardena A,Brogan PA,Trompeter RS,Dillon MJ

    更新日期:2002-05-01 00:00:00

  • Pediatric HIV: new opportunities to treat children.

    abstract:BACKGROUND:Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. OBJECTIVE:To summarize current data concerning new opportunities to improve the treatment of H...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903012377

    authors: Van der Linden D,Callens S,Brichard B,Colebunders R

    更新日期:2009-08-01 00:00:00

  • Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.

    abstract:INTRODUCTION:The late effects of cancer treatment have recently gained a worldwide ubiquitous interest among reproductive endocrinologists, oncologists, and all health care providers. Despite many publications on this subject, there are many equivocal issues necessitating summary. The case for and against using GnRH-ag...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1031654

    authors: Blumenfeld Z,Evron A

    更新日期:2015-05-01 00:00:00

  • Pharmacological management of renal fibrotic disease.

    abstract::Chronic kidney diseases frequently advance to end-stage renal failure, and the number of patients affected is steadily increasing worldwide. At the molecular level, progression of renal insufficiency correlates closely with ongoing pathological matrix protein expansion (i.e., renal fibrosis), in a manner independent o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.4.377

    authors: Gaedeke J,Neumayer HH,Peters H

    更新日期:2006-03-01 00:00:00

  • Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.

    abstract::Selective serotonin reuptake inhibitors (SSRIs) are now generally regarded as effective and better tolerated alternatives to tricyclic antidepressants (TCAs) for the treatment of depression. SSRIs also seem to be as well tolerated as moclobemide, mirtazapine, venlafaxine, reboxetine and nefazodone and show comparable ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.5.917

    authors: Mace S,Taylor D

    更新日期:2000-07-01 00:00:00

  • Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

    abstract:BACKGROUND:Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations. OBJECTIVE:To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use. METHODS:The structure and the mechanism of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802489569

    authors: Jayaweera DT,Espinoza L,Castro J

    更新日期:2008-12-01 00:00:00

  • Strategies in the treatment of HIV-1-associated adipose redistribution syndromes.

    abstract::HIV-1/highly active antiretroviral therapy-associated lipodystrophy syndrome (HALS) is presently the most common long-term adverse effect limiting the doubtless efficacy of antiretroviral therapy. It has a great impact on the quality of life of patients, it is stigmatising and its psychologically devastating consequen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.12.1871

    authors: del Mar Gutierrez M,Mateo G,Domingo P

    更新日期:2007-08-01 00:00:00

  • Starting aripiprazole long-acting-once-a-month early in treatment: why, how and for whom? Expert consensus and practical recommendations by a panel of Italian clinicians.

    abstract:INTRODUCTION:Aripiprazole long acting once-monthly (AOM) is approved for the treatment of schizophrenia in adults. Despite recent evidence of AOM efficacy in the acute treatment of schizophrenia, it is recommended that AOM should be started once the acute symptoms are controlled and patients are stabilized. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2016.1244526

    authors: Amodeo G,Candiracci C,Capecci I,De Filippis S,Giuliani S,Guerani G,Tomasetti C,Villari V,Fagiolini A

    更新日期:2016-11-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • Pharmacotherapeutic strategies for treating hypertension in patients with obesity.

    abstract:INTRODUCTION:Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT)...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1458092

    authors: Carnagarin R,Matthews V,Gregory C,Schlaich MP

    更新日期:2018-05-01 00:00:00

  • Exemestane in postmenopausal women with early or advanced breast cancer: a review.

    abstract:IMPORTANCE OF THE FIELD:Inhibition of the aromatase enzyme in postmenopausal women reduces levels of estrogens, which is of therapeutic value in hormone-sensitive breast cancer. Exemestane is a third-generation steroidal irreversible inactivator of the aromatase enzyme used in early and advanced breast cancer for the t...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.495945

    authors: Bertelli G,Gangadhara S

    更新日期:2010-08-01 00:00:00

  • Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.

    abstract:INTRODUCTION:Treatment of rheumatoid arthritis (RA) has markedly advanced by the advent of biologic disease-modifying antirheumatic drugs (DMARDs). However, they require special storage and transportation and remission is observed in ∼ 30%. Tofacitinib inhibits the nonreceptor tyrosine kinase family Janus kinase (JAK),...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.854771

    authors: Yamaoka K,Tanaka Y

    更新日期:2014-01-01 00:00:00

  • Insulin analogue therapy in pregnancies complicated by diabetes mellitus.

    abstract::Pregnancies complicated by diabetes mellitus (DM) include pregestational DM and gestational DM, defined as carbohydrate intolerance of variable severity first detected during pregnancy. DM leads to poor pregnancy outcome. The aim of treatment is to control maternal hyperglycaemia and to imitate postprandial insulin re...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.5.735

    authors: González C,Santoro S,Salzberg S,Di Girolamo G,Alvariñas J

    更新日期:2005-05-01 00:00:00

  • Which antihypertensive drugs are the most nephroprotective and why?

    abstract:IMPORTANCE OF THE FIELD:Hypertension is a major independent risk factor for kidney disease and for faster renal function loss. Choice of antihypertensive strategies with highest nephroprotective effect is crucial to prevent or reverse progression to end stage renal disease (ESRD). AREAS COVERED IN THIS REVIEW:The pres...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.521742

    authors: Cravedi P,Ruggenenti P,Remuzzi G

    更新日期:2010-11-01 00:00:00

  • Pharmacological management of depression in patients with multiple sclerosis.

    abstract:INTRODUCTION:The pharmacotherapeutic management of depression in patients with multiple sclerosis (MS) is a matter of debate that cannot be decided from the evidence available in the current literature. Therefore, its management essentially relies on the clinical experience of the prescribing clinician rather than on e...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1516207

    authors: Carta MG,Paribello P,Anastasia A,De Berardis D,Nardi AE,Fornaro M

    更新日期:2018-10-01 00:00:00

  • The treatment of Tourette's syndrome: current opinions.

    abstract::Correct education of the patient is one of the most important aspects in the treatment of Tourette's syndrome. Pharmacotherapy is often unsatisfactory and therefore should be limited to those patients who are significantly impaired. Therapy must be individualised and the most troublesome symptom should be targeted fir...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.3.7.899

    authors: Müller-Vahl KR

    更新日期:2002-07-01 00:00:00

  • An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma.

    abstract:INTRODUCTION:Hepatocellular carcinoma (HCC) is a frequent and severe complication of cirrhosis. Most HCC patients initially present with or progress to advanced stage disease and require systemic treatment. As hypervascularization is a major characteristic of HCC, antiangiogenic drugs have been tested. Areas covered: I...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1378346

    authors: Raoul JL,Gilabert M,Adhoute X,Edeline J

    更新日期:2017-10-01 00:00:00

  • A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.

    abstract::Following Huggins' original observation of the dependence of the prostate on androgens, testosterone suppression by either orchiectomy or oestrogen compounds (e.g., diethylstilbesterol [DES]) became the standard palliative treatment for advanced prostate cancer. Early studies showed testosterone suppression improved s...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.2.447

    authors: Perez-Marrero R,Tyler RC

    更新日期:2004-02-01 00:00:00

  • Intravesical therapy for bladder cancer.

    abstract:INTRODUCTION:Transurethral resection of bladder tumor (TURBT) is the gold standard initial diagnostic intervention for bladder cancer and provides diagnostic, therapeutic and prognostic benefit in non-muscle-invasive bladder cancer (NMIBC). However, TURBT alone is inadequate for optimal management of NMIBC, as patients...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1024656

    authors: Patel SG,Cohen A,Weiner AB,Steinberg GD

    更新日期:2015-04-01 00:00:00

  • Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

    abstract:INTRODUCTION:Over the past decade, treatment options for men with metastatic castration-resistant prostate cancer (CRPC) have expanded with the addition of abiraterone acetate (AA), enzalutamide, sipuleucel-T, radium-223, docetaxel and cabazitaxel. The optimal sequencing of therapies in the context of efficacy and know...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.995090

    authors: Zhang T,Zhu J,George DJ,Armstrong AJ

    更新日期:2015-03-01 00:00:00

  • Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

    abstract::Osteoporosis is a severe condition, associated with significant disability as a result of fragility fractures and increased mortality. Oral bisphosphonates effectively reduce the risk of osteoporotic fracture and are generally well tolerated. Unfortunately, patient outcomes are often compromised by suboptimal therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.13.2301

    authors: Reginster JY

    更新日期:2005-10-01 00:00:00